It is obvious compounding is driving the revenues

It is obvious compounding is driving the revenues for SCRC right now. Plus, RapiMeds potential in the $25B China OTC market is huge, and I agree with Mr. Schneiderman that RapiMeds could mirror compounding's impact on the bottom line. Then came the last two announcements signing agreements with United Apothecary in TN and Jungle Jims in Ohio. As the PRs stated, these two agreements span several pharmacies in several States. Cosmo you mentioned in your last post not to sell PIMD short. Just Google PIMD International and one would learn PIMD is a major wholesaler supplying medical devices, medications, and medical supplies to their existing accounts. Mr. Schneiderman already stated PIMD will supply UA with raw materials. However, and I'm just thinking out loud, has anyone given any thought to what would happen to SCRC's bottom line if PIMD would become the main wholesaler supplying all medical supplies, devices, and medications to UA and Jungle Jim? I know some have projected a $100M Annual Run Rate in the months to follow and based on what Mr. Schneiderman has developed here, I don't think it's out of the question as all. In fact, SCRC is already operating at a $60M ARR, $100M could very well be a low estimate. I think its all coming together and investors should be excited about the future and the long term potential offered by SCRC.